Wolf Gunter, Ziyadeh Fuad N
Klinik fur Innere Medizin III, University of Jena, Jena, Germany.
Nephron Physiol. 2007;106(2):p26-31. doi: 10.1159/000101797. Epub 2007 Jun 6.
One of the earliest clinically detectable abnormalities in diabetic nephropathy is microalbuminuria that eventually progresses to proteinuria. The degree of proteinuria correlates with the progression of glomerulosclerosis and tubulointerstitial fibrosis. In the glomerulus, a typical podocytopathy develops that participates in the initiation of glomerulosclerosis and the accelerated plasma protein leakage across the glomerular basement membrane (GBM) into Bowman's space. Downstream into the tubular compartment, the proteinuria induces proinflammatory and profibrogenetic injury in tubular cells which can facilitate the development of interstitial fibrosis and tubular atrophy. It has long been held that hemodynamic changes and the loss of negatively charged proteoglycans in the GBM are important mediators of proteinuria. More recently, biopsy studies in humans with diabetic kidney disease have provided strong evidence that podocytes are injured very early in the course of nephropathy. This podocytopathy--which is characterized by decreased podocyte number and/or density, GBM thickening and altered matrix composition, and foot process effacement--correlates closely with the development and progression of albuminuria. Components of the diabetic milieu (high glucose, accumulation of glycated proteins, high intrarenal angiotensin II (ANG II), and hypertension-induced mechanical stress) result in activation of cytokine systems, the most important of which are transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor-A (VEGF-A). ANG II-stimulated podocyte-derived VEGF, through a novel autocrine signaling loop, appears to be a major cause of nephrin downregulation and the development of proteinuria. Nephrin is an important protein of the slit diaphragm with anti-apoptotic signaling properties. TGF-beta1 causes podocyte apoptosis and an increase in extracellular matrix deposition. As a consequence, the denuded GBM adheres to Bowman's capsule initiating the development of glomerulosclerosis. Good control of hyperglycemia and hypertension and maximal inhibition of ANG II are essential steps in preventing the development and progression of diabetic nephropathy.
糖尿病肾病最早可临床检测到的异常之一是微量白蛋白尿,其最终会发展为蛋白尿。蛋白尿的程度与肾小球硬化和肾小管间质纤维化的进展相关。在肾小球中,会出现典型的足细胞病变,这种病变参与肾小球硬化的起始过程以及血浆蛋白加速通过肾小球基底膜(GBM)漏入鲍曼囊。在肾小管部分,蛋白尿会诱导肾小管细胞发生促炎和促纤维化损伤,这会促进间质纤维化和肾小管萎缩的发展。长期以来,人们一直认为血流动力学变化以及GBM中带负电荷的蛋白聚糖丢失是蛋白尿的重要介导因素。最近,对糖尿病肾病患者的活检研究提供了有力证据,表明足细胞在肾病病程的早期就受到损伤。这种足细胞病变的特征是足细胞数量和/或密度减少、GBM增厚和基质成分改变以及足突消失,与蛋白尿的发生和进展密切相关。糖尿病环境的成分(高血糖、糖化蛋白积累、肾内血管紧张素II(ANG II)升高以及高血压引起的机械应力)会导致细胞因子系统激活,其中最重要的是转化生长因子-β1(TGF-β1)和血管内皮生长因子-A(VEGF-A)。ANG II刺激足细胞衍生的VEGF通过一种新的自分泌信号通路,似乎是nephrin下调和蛋白尿发生的主要原因。Nephrin是裂孔隔膜的一种重要蛋白质,具有抗凋亡信号特性。TGF-β1导致足细胞凋亡并增加细胞外基质沉积。因此,裸露的GBM会粘附在鲍曼囊上,引发肾小球硬化的发展。良好地控制高血糖和高血压以及最大程度地抑制ANG II是预防糖尿病肾病发生和进展的关键步骤。